Natera is a global leader in precision medicine and cell-free DNA (cfDNA) testing, specializing in molecular diagnostics. Originally founded as Gene Security Network by Matthew Rabinowitz and Jonathan Sheena, the company was born out of a personal mission to improve genetic disease detection. By blending advanced molecular biology with proprietary bioinformatics and AI software, Natera delivers highly accurate, non-invasive genetic testing capable of detecting abnormal DNA down to a single molecule in a tube of blood.
The company's commercial operations are anchored by three major clinical pillars: women's health, oncology, and organ health. Its notable testing suites include Panorama for non-invasive prenatal screening, Signatera for customized cancer recurrence monitoring and molecular residual disease (MRD) tracking, and Prospera for evaluating early organ transplant rejection. Backed by over 400 peer-reviewed clinical publications, Natera's technology platform serves a wide client base of physicians, health networks, and biopharmaceutical partners.
Publicly traded on the NASDAQ under the ticker NTRA, the company is headquartered in Austin, Texas, and maintains high-throughput, CLIA-certified and CAP-accredited laboratory facilities across Texas, California, and Colorado. Natera operates with a heavily decentralized workforce where the majority of its functional staff are built into operations, clinical laboratory engineering, and commercial sales teams to support its rapidly expanding precision-diagnostics business.
